Greenwich LifeSciences, Inc.
$24.52
▼
-0.61%
2026-04-21 07:06:03
greenwichlifesciences.com
NCM: GLSI
Explore Greenwich LifeSciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$384.32 M
Current Price
$24.52
52W High / Low
$34.1 / $7.78
Stock P/E
—
Book Value
$0.16
Dividend Yield
—
ROCE
-631.87%
ROE
-5.43%
Face Value
—
EPS
$-1.46
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
4
Beta
1.53
Debt / Equity
—
Current Ratio
2.35
Quick Ratio
2.62
Forward P/E
-31.44
Price / Sales
—
Enterprise Value
$353.36 M
EV / EBITDA
-18.04
EV / Revenue
—
Rating
Strong Buy
Target Price
$47.5
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Quantum BioPharma Ltd. | $3.12 | — | $25.24 M | — | -300.19% | -3.47% | $52 / $2.85 | $1.81 |
| 2. | Maravai LifeSciences Holdings, Inc. | $3.61 | — | $928.01 M | — | -17.71% | -48.59% | $4.11 / $1.67 | $1.46 |
| 3. | Adicet Bio, Inc. | $8.67 | — | $83.2 M | — | -71.49% | -67.55% | $17.44 / $6.01 | $14.82 |
| 4. | Lite Strategy, Inc. | $1.19 | — | $42.54 M | 0% | -103.09% | -76.38% | $9 / $0.95 | $2.23 |
| 5. | ProKidney Corp. | $2.1 | — | $634.02 M | — | -54.13% | -43.17% | $7.13 / $0.54 | $-7.13 |
| 6. | PMGC Holdings Inc. | $3.32 | — | $6.35 M | — | -76.42% | -1.07% | $309.12 / $1.62 | $97.11 |
| 7. | Exicure, Inc. | $3.77 | — | $22.85 M | — | -99.65% | -92.47% | $12.65 / $3.1 | $0.62 |
Quarterly Results
Figures shown in M / B
| Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -4.17 M | -4.05 M | -3.28 M | -8.08 M | -2.73 M |
| Net Profit | -4.15 M | -4.03 M | -3.26 M | -8.04 M | -2.67 M |
| EPS in Rs | -0.3 | -0.29 | -0.24 | -0.58 | -0.19 |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -16.01 M | -9.33 M | -8.04 M | -4.6 M |
| Net Profit | -15.79 M | -8.89 M | -7.83 M | -4.57 M |
| EPS in Rs | -1.14 | -0.64 | -0.56 | -0.33 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 4.09 M | 6.99 M | 13.48 M | 27.22 M |
| Total Liabilities | 1.56 M | 0.29 M | 0.26 M | 0.39 M |
| Equity | 2.53 M | 6.7 M | 13.21 M | 26.83 M |
| Current Assets | 4.09 M | 6.99 M | 13.47 M | 27.2 M |
| Current Liabilities | 1.56 M | 0.29 M | 0.26 M | 0.39 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | -7.27 M | -6.48 M | -6.2 M | -4.29 M |
| Investing CF | — | — | — | — |
| Financing CF | 4.37 M | 0 M | -7.54 M | 2.84 M |
| Free CF | -7.27 M | -6.48 M | -6.2 M | -4.29 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -77.57% | -13.63% | -71.21% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.